Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2015 | review | Ausgabe 2/2015

memo - Magazine of European Medical Oncology 2/2015

New targets in breast cancer

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2015
Autoren:
MD Ami Jhaveri, MD, DPhil Lajos Pusztai

Abstract

In the past few years, the therapeutic strategies for breast cancer have broadened substantially beyond endocrine therapy, chemotherapy, and human epidermal growth factor receptor 2-targeted agents to include several new drugs with unique mechanism of actions including antibody–drug conjugates, inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway, cyclin-dependent kinases 4/6, histone deacetylases and the poly ADP ribose polymerase as well as immune checkpoint modulators. Novel clinical trial designs are also being implemented in the clinic to assess the therapeutic potential of targeting rare molecular abnormalities observed in breast cancers (fibroblast growth factor receptor amplification, inactivating mutations in BRCA, activating mutations in HER2, epidermal growth factor receptor, c-Kit, Akt, etc.).

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2015

memo - Magazine of European Medical Oncology 2/2015 Zur Ausgabe